Ovid Therapeutics Appoints New CFO Charles Carter Following CBFO Jeffrey Rona's Departure
OVID has more than doubled off its 52-week low of $0.331.
Summary
Ovid Therapeutics announced a leadership change, with Jeffrey Rona stepping down as Chief Business and Financial Officer and Charles Carter, previously SVP of Finance, appointed as the new CFO.
Key Events · Executive and Board Changes · OVID
-
Chief Business and Financial Officer Departs
Jeffrey Rona mutually agreed to transition from his roles as Chief Business and Financial Officer, principal financial officer, principal accounting officer, and secretary, effective July 6, 2026. His departure was not due to any disagreements with the company.
-
New Chief Financial Officer Appointed
Charles Carter, previously Senior Vice President of Finance and Financial Planning, has been appointed as the new Chief Financial Officer, principal financial officer, principal accounting officer, and secretary, effective July 6, 2026.
-
New CFO's Extensive Experience
Mr. Carter brings significant experience, having served as CFO for CERo Therapeutics Holdings, Inc., iCAD, Inc., and GI Dynamics, Inc., and as a Senior Director at Danforth Advisors, LLC, a strategic consulting firm for life sciences companies.
-
New CFO's Compensation Details
Mr. Carter will receive an annual base salary of $460,000, a target annual cash bonus of 35% of his base salary, and a restricted stock unit award of 50,000 shares vesting over two years. He is also eligible for an additional $75,000 cash bonus.
Analysis · OVID · Life Sciences
Ovid Therapeutics announced a significant executive transition with the mutual departure of its Chief Business and Financial Officer, Jeffrey Rona, and the appointment of Charles Carter as the new Chief Financial Officer. The filing explicitly states Rona's departure was not due to any disagreements, and Carter brings extensive experience from prior CFO roles at other public life sciences companies, ensuring continuity and strong financial leadership. This change is important for the company's strategic direction and financial management.
At the time of this filing, OVID was trading at $2.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $515.1M. The 52-week trading range was $0.33 to $3.11. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.